Kaikai Zhao

Dr. Kaikai Zhao

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 April 2022 in BMC Gastroenterology
Verified
Journal Article
Open access
PDF file
JQJunchao Qian
Junchao Qian
YSYoujiao Si
Youjiao Si
KZKe Zhou
Ke Zhou
YTYu Tian
Yu Tian
QGQisen Guo
Qisen Guo
JYJinming Yu
Jinming Yu
Background: This study aimed to determine the prognostic value of the sarcopenia on the progression free survival (PFS) and overall survival (OS) of esophageal squamous cell cancer (ESCC) patients who received radiotherapy (RT) or chemoradiotherapy (CRT). Methods: Data on clinicopathological characteristics and nutritional parameters were analyzed and correlated with PFS and OS, retrospectively. Skeletal muscle, subcutaneous, visceral and total fat tissue cross-sectional areas were evaluated on CT images at the midpoint of the 3rd lumbar vertebrae. A total of 213 patients were enrolled in this study. Results: Sarcopenia was significantly associated with subcutaneous fat content. The univariate analysis demonstrated that OS was superior in patients with non-sarcopenia, non-alcohol, NRI ≥ 100, albumin ≥ 40 g/L, TATI > 83.0, SATI > 27.8, VATI > 49, non-anemia, cervical and upper-thoracic ESCC, T stage 1–2, N stage 0–1 and TNM stage I–II. In the multivariate analysis, sarcopenia, albumin, N stage and TNM stage were identified as independent prognostic factors of survival. This study demonstrated that sarcopenia was related to worse PFS and OS in patients with ESCC who received RT or CRT. Conclusions: Sarcopenia is considered to be a useful predictor in patients with ESCC who received RT or CRT. This study also provided a conceptual basis for further prospective research on the application of the sarcopenia for patients receiving RT or CRT for intermediate- and advanced-stage ESCC.

6 October 2024 in Scientific Reports
Verified
Journal Article
Open access
PDF file
YSYoujiao Si
Youjiao Si
ZZZhonghua Zhao
Zhonghua Zhao
XMXiangjiao Meng
Xiangjiao Meng
KZKaikai Zhao
Kaikai Zhao
Angiogenesis, metastasis, and resistance to therapy are all facilitated by cancer-associated fibroblasts (CAFs). A CAF-based risk signature can be used to predict patients’ prognoses for Lung adenocarcinoma (LUAD) based on CAF characteristics. The Gene Expression Omnibus (GEO) database was used to gather signal-cell RNA sequencing (scRNA-seq) data for this investigation. The GEO and TCGA databases were used to gather bulk RNA-seq and microarray data for LUAD. The scRNA-seq data were analyzed using the Seurat R program based on the CAF markers. Our goal was to use differential expression analysis to discover differentially expressed genes (DEGs) across normal and tumor samples in the TCGA dataset. Pearson correlation analysis was utilized to discover prognostic genes related with CAF, followed by univariate Cox regression analysis. Using Lasso regression, a risk signature based on CAF-related prognostic genes was created. A nomogram model was created based on the clinical and pathological aspects. 5 CAF clusters were identified in LUAD, 4 of which were associated with prognosis. From 2811 DEGs, 1002 genes were found to be significantly correlated with CAF clusters, which led to the creation of a risk signature with 8 genes. These 8 genes were primarily connected with 41 pathways, such as antigen paocessing and presentation, apoptosis, and cell cycle. Meanwhile, the risk signature was significantly associated with stromal and immune scores, as well as some immune cells. Multivariate analysis revealed that risk signature was an independent prognostic factor for LUAD, and its value in predicting immunotherapeutic outcomes was confirmed. A novel nomogram integrating the stage and CAF-based risk signature was constructed, which exhibited favorable predictability and reliability in the prognosis prediction of LUAD. CAF-based risk signatures can be effective in predicting the prognosis of LUAD, and they may provide new strategies for cancer treatments by interpreting the response of LUAD to immunotherapy.

19 October 2021 in Cancer Medicine
Verified
Journal Article
Open access
PDF file
YCYu Chen
Yu Chen
XLXinchao Liu
Xinchao Liu
ZHZhaoqin Huang
Zhaoqin Huang
KZKaikai Zhao
Kaikai Zhao
YWYao Wang
Yao Wang
XMXiangjiao Meng
Xiangjiao Meng
Background: The safety of thoracic radiotherapy (TRT) after programmed death 1/programmed death ligand 1 (PD‐(L)1) inhibitor treatment in patients with lung cancer was scarcely reported. This retrospective study was conducted to evaluate the incidence, severity, and risk factors of symptomatic treatment‐related pneumonitis in patients with lung cancer who received this sequential combination.Methods: We conducted a retrospective study of a cohort of patients with lung cancer who received TRT after at least two cycles of PD‐(L)1 inhibitor treatment between January 2018 and August 2020. Treatment‐related pneumonitis was evaluated and analyzed to illustrate the safety profile of this sequential combination. Potential risk factors were explored by univariate and multivariate logistic regression analyses.Results: Among the 828 patients with prior PD‐(L)1 inhibitor treatment, 96 patients receiving subsequent TRT were included in the analysis. Of these, 49 patients (51%) received radical TRT while 47 patients (49%) received palliative TRT. The median total dose was 52 Gy (IQR 50–60 Gy). The median time from the initiation of PD‐(L)1 inhibitor treatment to TRT was 4.8 months (1.6–14.1 months) with most of the patients (74%) administering no less than four cycles of PD‐(L)1 inhibitor. During follow‐up, 47 patients (48.96%) developed symptomatic treatment‐related pneumonitis (grade 2 n = 28, grade ≥3 n = 19) while six patients (6.25%) suffered from fatal toxicity. The median time of pneumonitis onset after completion of TRT was 35 days (0–177 days) with six patients developing during TRT. Pulmonary emphysema and lung V20 were demonstrated to be independent risk factors of symptomatic pneumonitis (OR: 5.67, 95% CI: 1.66–19.37, p = 0.006; OR: 3.49, 95% CI: 1.41–8.66, p = 0.007, respectively).Conclusion: TRT after PD‐(L)1 inhibitor treatment resulted in significantly increased incidence and severity of treatment‐related pneumonitis in patients with lung cancer. Intensive attention should be emphasized to the safety of this sequential combination in clinical practice.

21 October 2020 in Radiation Oncology
Verified
Journal Article
Open access
PDF file
KZKaikai Zhao
Kaikai Zhao
YSYoujiao Si
Youjiao Si
LSLiangchao Sun
Liangchao Sun
XMXiangjiao Meng
Xiangjiao Meng
JYJinming Yu
Jinming Yu
Introduction: There is no standard treatment for locoregional recurrent (LR) esophageal squamous cell carcinoma (ESCC) patients treated with radiotherapy (RT) previously. This retrospective study aimed to examine the efficacy and toxicity of re-irradiation (re-RT) for ESCC patients with LR. Patients and methods: A total of 252 patients were enrolled. Gross tumor volumes for re-RT were defined using contrast enhanced computed tomography and/or positron emission tomography/computed tomography. Overall survival (OS), after recurrence survival (ARS) and toxicities were assessed. Results: Through a median follow-up of 38 months, the median OS and ARS were 39.0 and 13.0 months, respectively. The 6-, 12-, and 24-month ARS rates were 81.9%, 50.5%, and 21.8%, respectively. Multivariate analyses showed that chemotherapy, esophageal stenosis and recurrence-free interval (RFI) may be independent prognostic factors for ARS. The incidence of esophageal fistula/perforation (EP), radiation-induced pneumonitis and esophagorrhagia was 21.4%, 12.8% and 9.1%, respectively. RFI ≤ 12 months, esophageal stenosis and fat space between tumor and adjacent tissue disappeared were independent risk factors for the development of EP after re-RT. Conclusions: Re-RT was feasible for LR ESCC patients after RT initially, the complication occurred in re-RT is acceptable. Patients with RFI ≤ 12 months, esophageal stenosis and fat space between tumor and adjacent tissue disappeared should be closely observed during and after re-RT.

23 December 2022 in Medicine
Verified
Journal Article
Open access
YSYoujiao Si
Youjiao Si
PXPeng Xu
Peng Xu
AXAihua Xu
Aihua Xu
PWPeiyuan Wang
Peiyuan Wang
KZKaikai Zhao
Kaikai Zhao
The geriatric nutritional risk index (GNRI) has been shown to be associated with the prognosis of cancer patients except for hepatocellular carcinoma (HCC) patients after transarterial chemoembolization (TACE). Our aim is to examine the association between the GNRI and long-term prognosis in patients with HCC who underwent TACE. Patients with HCC who underwent TACE were enrolled. The relationship between the patient characteristics and GNRI were compared, and the independent prognostic factors were investigated. Nomogram performance was assessed via the concordance index (C-index) and calibration plots. Decision curve analysis (DCA) was performed to evaluate the net benefit of the nomogram. A total of 235 patients met the inclusion criteria. Compared with the parameters of the high GNRI group, low GNRI was significantly associated with hypertension, ascites, body mass index, tumor size, anemia, Child-Turcotte-Pugh class. The univariate analysis demonstrated that overall survival (OS) was inferior when GNRI < 98, tumor size ≥ 5cm, vascular invasion, alpha-fetoprotein level ≥ 400, Barcelona clinical liver cancer stage B to C and TACE times < 3. The multivariate analysis revealed that GNRI < 98, tumor size ≥ 5cm, tumor number ≥ 2, alpha-fetoprotein level ≥ 400 and TACE times < 3 were independent predictors of a poor OS. In the validation step, OS was shown to be well calibrated (C-index = 0.724), and a satisfactory clinical utility was proven by DCA. Low GNRI score was associated with a shorter OS in patients undergoing TACE.

20 December 2025 in Therapeutic Advances in Medical Oncology
Verified
Journal Article
Open access
WYWenhua Yun
Wenhua Yun
ALAiling Liu
Ailing Liu
JWJunxu Wen
Junxu Wen
KZKaikai Zhao
Kaikai Zhao
XMXiangjiao Meng
Xiangjiao Meng
Background: Leptomeningeal metastasis (LM) is a serious complication of advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutation. There are no guidelines or consensus on the optimal treatment regimens and strategies for LM yet. Objectives: To analyze the influence of different treatment methods on the survival of patients and explore the factors influencing the prognosis of patients with LM. We profiled the cerebrospinal fluid (CSF) immune microenvironment in patients with LM using genetic and lymphocyte subset analyses. Design: We identified 209 patients with advanced NSCLC who developed LM without extracranial progression following third-generation EGFR-tyrosine kinase inhibitor (EGFR-TKIs) therapy. Their medical records were reviewed to extract relevant data. Methods: Survival curves were plotted and prognostic factors were analyzed using R software and SPSS statistical software, respectively. Statistical analysis was performed on the results of CSF genetic testing and lymphocyte subset profiling. Results: The median overall survival (mOS) time of patients who received high-dose EGFR-TKI monotherapy or in combination with other treatments was longer than that of patients with standard-dose EGFR-TKI combined with other treatments (19.7 vs 9.0 months), patients who received EGFR-TKI combined with anti-angiogenic drugs was longer than that of patients who did not combine anti-angiogenic drugs (19.6 vs 12.0 months). Analysis of CSF genomic profiles from 124 patients with LM identified a greater frequency of EGFR L858R (64.5%) versus exon 19 deletions (35.5%). We also observed a significant enrichment of B-cell subsets in the CSF of patients with LM compared to those without, and the B-cell count gradually decreased during the treatment process. Conclusion: For patients developing LM after third-generation EGFR-TKI resistance, high-dose EGFR-TKIs or EGFR-TKIs combined with anti-angiogenic drugs represent viable therapeutic strategies, and B lymphocytes may serve as a promising immunotherapy target for LM.